0001171000-17-000039.txt : 20170705
0001171000-17-000039.hdr.sgml : 20170705
20170705121123
ACCESSION NUMBER: 0001171000-17-000039
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170701
FILED AS OF DATE: 20170705
DATE AS OF CHANGE: 20170705
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nexvet Biopharma plc
CENTRAL INDEX KEY: 0001618561
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK
STREET 2: RAHAN ROAD
CITY: TULLAMORE , CO. OFFALY
STATE: L2
ZIP: R35 FR98
BUSINESS PHONE: 353 1 215 8100
MAIL ADDRESS:
STREET 1: UNIT 5, SRAGH TECHNOLOGY PARK
STREET 2: RAHAN ROAD
CITY: TULLAMORE , CO. OFFALY
STATE: L2
ZIP: R35 FR98
FORMER COMPANY:
FORMER CONFORMED NAME: NEXVET BIOPHARMA Ltd
DATE OF NAME CHANGE: 20140903
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Heffernan Mark
CENTRAL INDEX KEY: 0001632439
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36828
FILM NUMBER: 17946838
MAIL ADDRESS:
STREET 1: C/O NEXVET BIOPHARMA PLC
STREET 2: NATL INST, FOSTERS AVENUE, MOUNT MERRION
CITY: BLACKROCK
STATE: L2
ZIP: 00000
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2017-07-01
0001618561
Nexvet Biopharma plc
NVET
0001632439
Heffernan Mark
C/O NEXVET BIOPHARMA PLC
UNIT 5, SRAGH TECHNOLOGY PARK, RAHAN RD
TULLAMORE
L2
R35 FR98
IRELAND
0
1
0
0
Chief Executive Officer
Ordinary Shares
2017-07-01
4
M
0
25000
.125
A
74167
D
Ordinary Shares
2017-07-01
4
M
0
35643
.125
A
109810
D
Ordinary Shares
243587
I
By Mark Andrew and Patricia Louise Heffernan <M&T Heffernan A/C>
Restricted Share Units
.125
2017-07-01
4
M
0
25000
0
D
2017-07-01
2020-07-01
Ordinary Shares
25000
50000
D
Restricted Share Units
.125
2017-07-01
4
M
0
35643
0
D
2017-07-01
2020-07-01
Ordinary Shares
35643
106929
D
The reporting person and his spouse share voting and dispositive power with respect to these reported securities.
25,000 of the Restricted Share Units vested and became convertible on 7/1/17 and 25,000 of the Restricted Share Units shall vest and become convertible on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.
35,643 of the Restricted Share Units vested and became convertible on 7/1/17 and 35,643 of the Restricted Share Units shall vest and become convertible on each of 7/1/18, 7/1/19 and 7/1/20, in each case subject to payment of the nominal value per share to Issuer within 30 days of vesting.
/s/ Mark Heffernan by Geraldine T. Farrell, Attorney-in-Fact
2017-07-03